First-ever recommendations for establishing dedicated adult sickle cell disease treatment centers published
Directors of the top sickle cell disease (SCD) programs in
the US recently
published the first set of recommendations for establishing SCD centers aimed at improving access to care for adults living with the debilitating, lifelong blood disease. The recommendations, which resulted from a study done in preparation for an American Society of Hematology (ASH) workshop in 2019, outline the essential components that must be in place to establish an adult SCD treatment center.
SCD patients in the US often lack access to comprehensive care to manage their condition, help them prevent emergency department visits, and avoid serious complications.
The recommendations, published in Blood Advances, codify the required components of establishing SCD adult care centers. These requirements include:
The paper makes recommendations for additional important, but not required, personnel such as clinic managers, behavioral health staff and psychologists, physical and occupational therapists, and pharmacists. Altogether, the recommendations define comprehensive care for SCD as team-based, holistic, and tailored to the unique needs of individuals with this condition.
SCD is the most common inherited red blood cell disorder in
the US
, affecting an estimated 100,000 people. According to the Centers for Disease Control and Prevention, SCD affects one out of every 365 Black or African American births and one out of every 16,300 Hispanic American births. Individuals with SCD suffer from acute pain episodes and chronic pain, and may be affected by an array of other organ complications, which can cause disability or even death.
Since the universal adoption of newborn screening in
the US
in 2006, care for children living with SCD has improved. However, their access to appropriate, quality care often suffers in the transition to adulthood because of a shortage of specialized providers (adult patients are reportedly more likely to receive care in community hospitals, where SCD-specific experience is less common) and gaps in coordination among the various primary care physicians and specialists who might treat a patient with this disease. Other barriers to specialized care for adults with SCD include those related to health insurance cost and coverage, socioeconomic status, and co-existing conditions.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.